ClinicalTrials.gg
RecruitingNCT06564272Updated Aug 23, 2024

A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma

A Phase 2 interventional study of KC1036 in Ewing Sarcoma, sponsored by Beijing Konruns Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-08-23.

Sponsored by Beijing Konruns Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 22 studies in Sarcoma, Ewing with a site in China — 10 open to participants now, 13 under way, none of them phase 3. Sarcoma, Ewing · China.

Planned enrollment
9th of 16
30 · median 37
Started
2024
with 5 others
Phase 2
6 of 22
3 open now
Primary completion
2027-04
later than 4 of 12 live
Registered
15th of 22
by date
Lead sponsor
1 of 22
Beijing Konruns Pharmaceutical Co., Ltd.

Among the 22 studies in Sarcoma, Ewing with a site in China, this one is the 9th largest by planned enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2024, is one of 6 in phase 2, reaches primary completion later than 4 of the 12 other live ones, and was the 15th registered.

Sarcoma, Ewing

250 studies on the registry are indexed under Sarcoma, Ewing; 69 are open to participants now.

Browse Sarcoma, Ewing studies →

Open to participants now

10 of the 22 studies in Sarcoma, Ewing with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 58 Sarcoma, Ewing studies recruiting now, 19 (33%) set no upper age limit and 36 (62%) stop at 75 or younger; 49 take children under 18; 2 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Sarcoma, Ewing with a site in China, or all of them as a file.
02

Study summary

This open-label, single-arm clinical trial is to evaluate the safety and effectiveness of KC1036 in treating adolescents aged 12 and above with advanced Ewing sarcoma. Participants will take KC1036 once daily, with each treatment cycle lasting 4 weeks.

03

Conditions studied

  • Ewing Sarcoma

Browse trials for

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 12 and less than 18 years;
  • Diagnosed with Ewing sarcoma confirmed by histopathological examination;
  • Patients with locally advanced or Ewing sarcoma that is unresectable or has failed standard treatment, and for whom no other treatment options are available as assessed by the investigator;
  • Body weight of ≥30 kg;
  • performance status (≥16 years) or Lansky performance status (\<16 years) score of ≥60%;
  • Patients with at least one according to v1.1 (Response Evaluation Criteria in Solid Tumors);
  • Expected survival of more than 12 weeks;
  • Sufficient organ and bone marrow function;
  • Female patients who have started menstruating must have a negative pregnancy test;
  • The patient and their legal guardians understand and are willing to participate in the trial, and have signed the form.

Exclusion criteria

Exclusion Criteria:

  • Patients with primary central nervous system tumors;
  • Presence of central nervous system as diagnosed by imaging;
  • History of or concurrent other within the past 5 years;
  • Gastrointestinal abnormalities;
  • Cardiovascular or cerebrovascular abnormalities;
  • Patients who have previously received VEGFR-TKI small molecule treatment;
  • Currently participating in another therapeutic clinical trial; received any anticancer treatment within 2 weeks or 5 half-lives (whichever is longer) before the start of the study treatment; received whole-brain radiation therapy within 14 days before the start of the study treatment; received stereotactic radiosurgery within 7 days before the start of the study treatment; or received herbal or traditional Chinese medicine for anticancer purposes within 2 weeks before the study treatment;
  • Underwent major surgery within 2 months before enrollment or have not fully recovered, or plan to undergo surgery during the current study period;
  • Persistent toxicity from previous anticancer treatment that has not improved to ≤ Grade 1 (according to v5.0), excluding alopecia;
  • Unhealed skin wounds, surgical sites, traumatic sites, severe mucosal ulcers, or fractures;
  • Uncontrolled significant pleural effusion, ascites, or pericardial effusion;
  • Active bacterial, viral, or fungal infections; unexplained fever >38.5°C within 2 weeks before enrollment;
  • surface antigen (HBsAg) positive with HBV-DNA ≥500 IU/mL or 2500 copies/mL; virus (HCV) antibody positive with HCV RNA ≥200 IU/mL or positive test results; -positive individuals;
  • Presence of psychiatric or neurological disorders; or cognitive impairment;
  • Fertile patients (e.g., females who have started menstruating or males who have started ejaculating) who do not agree to use (e.g., birth control pills or condoms) during the study and for 6 months after the study ends;
  • Patients with insufficient compliance as evaluated by investigator;
  • The investigator believes that it is not suitable to patient in this clinical trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    KC1036

    oral administration QD

    Drug: KC1036

Interventions

  • DrugKC1036

    For patients weighing between 30 kg and less than 50 kg, administer 40 mg QD of KC1036. For patients weighing between 50 kg and less than 70 kg, administer 50 mg QD of KC1036. For patients weighing 70 kg or more, administer 60 mg QD of KC1036. 4 weeks as a cycle.

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Incidence of treatment-related AEs

    Time frame: approximately 3 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    Overall response rate (ORR) was defined as the percentage of participants with a best overall complete response (CR) or partial response (PR) per RECIST 1.1.

    Time frame: approximately 3 years

  2. Progression-free survival (PFS)

    Progression-free survival (PFS) was defined as the time from the start date of study drug to the date of the first radiologically documented progressive disease (PD) per RECIST 1.1 or death due to any cause.

    Time frame: approximately 3 years

  3. Disease Control Rate (DCR)

    Disease Control Rate (DCR) was defined as the percentage of participants with a best overall complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1.

    Time frame: approximately 3 years

  4. Duration of Response (DOR)

    Duration of response (DOR) was defined as the time from first documented response (partial response (PR) or complete response (CR)) to the date of first documented disease progression (PD) or death due to any cause, among patients with a confirmed PR or CR per RECIST 1.1.

    Time frame: approximately 3 years

07

Study locations

1 of 1 sites recruiting
  • Beijing Children's Hospital Affiliated to Capital Medical University
    Beijing, Beijing 100045, China
    Recruiting
    • Huanming Wang, Ph.D · Contactwanghuanmin@bch.com.cn · 010-88324973
    • Xin Ni, Ph.D · Principal investigator
    • Huanming Wang, Ph.D · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Apr 2027, 30 months later.

Of 39 phase 2 interventional studies under Sarcoma, Ewing, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 92. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 21, 2024
StartEst.
Sep 27, 2024
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2028
Last update
Aug 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06564272
Lead sponsor
Beijing Konruns Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Aug 21, 2024
Start date
Sep 27, 2024 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Aug 23, 2024

Study contacts

Xin Ni
Contact
nixin@bch.com.cn
010-88324973
Huanmin Wang
Contact
wanghuanmin@bch.com.cn
010-88324973
Huanmin Wang
principal investigator · Beijing Children's Hospital Affiliated to Capital Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AXL/FLT3/VEGFR2 Inhibitor KC1036

Start the discussion